XP0 Stock Overview
A neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Xenon Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.00 |
| 52 Week High | US$46.60 |
| 52 Week Low | US$30.60 |
| Beta | 1.25 |
| 11 Month Change | 6.22% |
| 3 Month Change | 12.64% |
| 1 Year Change | 33.99% |
| 33 Year Change | 81.42% |
| 5 Year Change | 238.84% |
| Change since IPO | 245.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| XP0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 10.8% | 1.1% | 1.3% |
| 1Y | 34.0% | -18.5% | 7.9% |
Return vs Industry: XP0 exceeded the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: XP0 exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| XP0 volatility | |
|---|---|
| XP0 Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: XP0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: XP0's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 255 | Ian Mortimer | www.xenon-pharma.com |
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Xenon Pharmaceuticals Inc. Fundamentals Summary
| XP0 fundamental statistics | |
|---|---|
| Market cap | €3.12b |
| Earnings (TTM) | -€202.19m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-15.4x
P/E RatioIs XP0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XP0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$192.00m |
| Gross Profit | -US$192.00m |
| Other Expenses | US$21.39m |
| Earnings | -US$213.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.80 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did XP0 perform over the long term?
See historical performance and comparison